Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Arius Research Inc.

Division of Roche

Latest From Arius Research Inc.

Amorfix appoints Warren Whitehead CFO

Warren Whitehead

Stockwatch: The Canadian patient

It has not been a good week for Canadian biotech. The sell-off of the crown jewels at QLT (, 25 September 2012), the return of rights to Cardiome (, 27 September 2012), the loss of a court case at Tekmira and the failure to receive fast-track NDA status at Aeterna Zentaris have left biotech investors north of the border wondering if there is much of a home-grown sector left.

Cardiovascular Immune Disorders

Tiny Inhibrx signs '$500 million' preclinical antibody outlicensing deal with Celgene

An eight-person biotechnology firm in San Diego called Inhibrx has entered into an option and license agreement with Celgene worth up to $500 million in upfront and milestone payments plus royalties. The deal centres around a preclinical antibody asset, but neither party has disclosed which antibody or its target or the disease it might address.

Cancer Orthopedics

Amorfix makes R&D appointment

Amorfix Life Sciences, a Canadian theranostics company developing products and diagnostics for misfolded proteins in brain-wasting diseases and cancer, has appointed Dr Robert Gundel vice-president of R&D. He has 25 years' experience in the industry, having worked at Boehringer Ingelheim, Bayer and Arius Research (Roche). Before taking his role with Amorfix, Dr Gundel served as chief scientific officer at Heat Biologics, and before that was vice-president and head of research at Elusys Therapeutics. Last week, Amorfix announced that it was in discussions with potential partners to further develop its amyloid lateral sclerosis programme, which includes antibodies and vaccines for misfolded SOD1 (copper-zinc superocide dismutase), which it has identified, co-located with beta-amyloid, in the brains of patients with Alzheimer's disease (, January 4th, 2010).

Cancer Neurology
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • Canada
  • Parent & Subsidiaries
  • Roche
  • Senior Management
  • David S Young, MD, Pres. & CEO
    Warren Whitehead, CFO
    Susan Hahn, PhD, VP, Dev.
  • Contact Info
  • Arius Research Inc.
    Phone: (416) 862-2323
    55 York St.
    15th Fl.
    Toronto, M5J 1R7